These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34571023)

  • 41. Stimulant treatment over 5 years: effects on growth.
    Charach A; Figueroa M; Chen S; Ickowicz A; Schachar R
    J Am Acad Child Adolesc Psychiatry; 2006 Apr; 45(4):415-21. PubMed ID: 16601646
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Growth Trajectories in Stimulant-Treated Children Ages 6 to 12: An Electronic Medical Record Analysis.
    Biederman J; DiSalvo M; Green A; Hutt Vater C; Driscoll H; Faraone SV
    J Dev Behav Pediatr; 2023 Feb-Mar 01; 44(2):e80-e87. PubMed ID: 36750982
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Callous-unemotional traits, proactive aggression, and treatment outcomes of aggressive children with attention-deficit/hyperactivity disorder.
    Blader JC; Pliszka SR; Kafantaris V; Foley CA; Crowell JA; Carlson GA; Sauder CL; Margulies DM; Sinha C; Sverd J; Matthews TL; Bailey BY; Daviss WB
    J Am Acad Child Adolesc Psychiatry; 2013 Dec; 52(12):1281-93. PubMed ID: 24290461
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects.
    Biederman J; Spencer TJ; Monuteaux MC; Faraone SV
    J Pediatr; 2010 Oct; 157(4):635-40, 640.e1. PubMed ID: 20605163
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
    CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Attention-deficit/hyperactivity disorder and obesity in US males and females, age 8-15 years: National Health and Nutrition Examination Survey 2001-2004.
    Byrd HC; Curtin C; Anderson SE
    Pediatr Obes; 2013 Dec; 8(6):445-53. PubMed ID: 23325553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Paying attention to stimulants: height, weight, and cardiovascular monitoring in clinical practice.
    Towbin K
    J Am Acad Child Adolesc Psychiatry; 2008 Sep; 47(9):977-80. PubMed ID: 18580503
    [No Abstract]   [Full Text] [Related]  

  • 48. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of Methylphenidate on Sleep Functioning in Children with Attention-Deficit/Hyperactivity Disorder.
    Becker SP; Froehlich TE; Epstein JN
    J Dev Behav Pediatr; 2016 Jun; 37(5):395-404. PubMed ID: 27011002
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of osmotic-release methylphenidate on height and weight in children with attention-deficit hyperactivity disorder (ADHD) following up to four years of treatment.
    Durá-Travé T; Yoldi-Petri ME; Gallinas-Victoriano F; Zardoya-Santos P
    J Child Neurol; 2012 May; 27(5):604-9. PubMed ID: 22190507
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Body mass index of children with attention-deficit/hyperactivity disorder.
    Dubnov-Raz G; Perry A; Berger I
    J Child Neurol; 2011 Mar; 26(3):302-8. PubMed ID: 20929910
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Growth dysregulation and ADHD: an epidemiologic study of children in France.
    Faraone SV; Lecendreux M; Konofal E
    J Atten Disord; 2012 Oct; 16(7):572-8. PubMed ID: 21817155
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes in Sleep Problems Across Attention-Deficit/Hyperactivity Disorder Treatment: Findings from the Multimodal Treatment of Attention-Deficit/Hyperactivity Disorder Study.
    Ricketts EJ; Sturm A; McMakin DL; McGuire JF; Tan PZ; Smalberg FB; McCracken JT; Colwell CS; Piacentini J
    J Child Adolesc Psychopharmacol; 2018 Dec; 28(10):690-698. PubMed ID: 30388029
    [No Abstract]   [Full Text] [Related]  

  • 55. [Nutrition and attention deficit hyperactivity disorder: developmental follow-up of the anthropometric variables of a group of patients receiving treatment with osmotic controlled-release methylphenidate].
    Dura-Trave T; Yoldi-Petri ME; Zardoya-Santos P
    Rev Neurol; 2011 Sep; 53(5):257-64. PubMed ID: 21796603
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Associations between Attention-Deficit Hyperactivity Disorder (ADHD) Treatment and Patient Nutritional Status and Height.
    Granato MF; Ferraro AA; Lellis DM; Casella EB
    Behav Neurol; 2018; 2018():7341529. PubMed ID: 30386441
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of long-term treatment with stimulant medication on growth?
    Poulton A
    J Am Acad Child Adolesc Psychiatry; 2007 Mar; 46(3):305. PubMed ID: 17314713
    [No Abstract]   [Full Text] [Related]  

  • 58. Open-Label Dose Optimization of Methylphenidate Extended-Release Orally Disintegrating Tablet in a Laboratory Classroom Study of Children with Attention-Deficit/Hyperactivity Disorder.
    Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
    J Child Adolesc Psychopharmacol; 2021 Jun; 31(5):342-349. PubMed ID: 34081560
    [No Abstract]   [Full Text] [Related]  

  • 59. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of Coexisting Conditions, Attention-Deficit/Hyperactivity Disorder Medication Choice, and Likelihood of Improvement in Preschool-Age Children: A Developmental Behavioral Pediatrics Research Network Study.
    Deavenport-Saman A; Vanderbilt DL; Harstad E; Shults J; Barbaresi W; Bax A; Cacia J; Friedman S; LaRosa A; Loe I; Mittal S; Blum N
    J Child Adolesc Psychopharmacol; 2022 Aug; 32(6):328-336. PubMed ID: 35787014
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.